Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Basilea Pharmaceutica ( OTC:BPMUF ) said Wednesday revenue contributions from Cresemba and Zevtera are expected to amount to about CHF 122 million for fiscal 2022. Total revenue, which includes BARDA reimbursements, proceeds from oncology transactions and other revenue in addition to ...
Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17% Significant proceeds from oncology transactions Following pre-NDA (New Drug Application) meeting held with FDA in Q4 2022 ...
Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 09, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that ...
Basilea Pharmaceutica ( OTC:BPMUF ) announced that it has fully repaid its 2.75% convertible bonds, which were due on December 23, 2022, with an outstanding nominal amount of CHF113.8M. Adesh Kaul, CFO, stated: “We are very pleased to have fully redeemed the 2022 convertible bo...
Basilea Pharmaceutica AG (BPMUF) Q2 2022 Earnings Conference Call August 16, 2022, 10:00 ET Company Participants David Veitch - CEO Adesh Kaul - CFO Marc Engelhardt - Chief Medical Officer Conference Call Participants Brian White - Calvine Partners ...
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2022 Q2 earnings call. For further details see: Basilea Pharmaceutica AG 2022 Q2 - Results - Earnings Call Presentation
Basilea Pharmaceutica AG ( OTC:BPMUF ): 1H GAAP EPS of -CHF1.03. Revenue of CHF58.6M (+8.1% Y/Y) beats by CHF14.31M . For further details see: Basilea Pharmaceutica AG GAAP EPS of -CHF1.03, revenue of CHF58.6M beats by CHF14.31M
The following slide deck was published by Basilea Pharmaceutica AG in conjunction with their 2021 Q4 earnings call. For further details see: Basilea Pharmaceutica AG 2021 Q4 - Results - Earnings Call Presentation
Basilea Pharmaceutica AG (BPMUF) Q4 2021 Earnings Conference Call February 15, 2022 10:00 a.m. ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgera...
Basilea Pharmaceutica AG press release (OTC:BPMUF): FY GAAP EPS of -CHF 0.58. Revenue of CHF 148.1M (+16.1% Y/Y). For 2022, Total revenue of CHF 106M – 112M; Cresemba & Zevtera related revenue is expected to amount to CHF 98M – 104M. Net cash used in operating acti...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...